Browsing by Author "Oktem, Mesut"

Now showing 1 - 2 of 2

The Effect of Captopril on Endometriotic Implants in A Rat Model
(2014) Oktem, Mesut; Ozcan, Pinar; Erdem, Ozlem; Karakaya, Cengiz; Cenksoy, Cahit; Guner, Haldun; Karabacak, Onur; Dursun, Polat; 25090631
Objective: To determine the effects of captopril on experimentally induced endometriosis in a rat model. Study design: Twenty-four adult, mature female Wistar-Albino rats in which endometriotic implants were induced by transplanting autologous uterine tissue to ectopic sites on the peritoneum. After the endometriotic implants were formed surgically, the 24 rats were randomly divided into three groups. Group 1 (captopril group, eight rats) were given 50 mg kg(-1) d(-1) of oral captopril for 21 d. Group 2 (leuprolide acetate group, eight rats) were given a single 1 mg kg(-1) subcutaneous injection of leuprolide acetate. Group 3 (control) were given no medication and served as controls (eight rats). The surface area of the endometriotic implants and the score of histologic analysis. Also, VEGF and MCP-1 levels in peritoneal fluids and bloods were analyzed. Results: At the beginning of the medical treatment, the mean surface areas of the endometriotic implants were comparable in all three groups. At the end of the treatment the mean implant surface area in the captopril group and leuprolide acetate group was less than that in the control group. Mean histopathological examination score for the implants post treatment was lower in the captopril and leuprolide acetate groups. Peritoneal fluids VEGF level in the captopril and leuprolide acetate groups was lower than that in the control group. The post-treatment MCP-1 level was also lower in the captopril and leuprolide acetate groups than in the control group. The serum VEGF and MCP-1 levels post treatment were significantly lower in the captopril and leuprolide acetate groups than in the control group. Conclusion: Administration of captopril reduced the size and progression of endometriotic lesions in a rat model. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
The effect of raloxifene on left ventricular hypertrophy in postmenopausal women: A prospective, randomized, and controlled study
(2015) Bal, Ugur Abbas; Atar, Ilyas; Oktem, Mesut; Zeyneloglu, Hulusi Bulent; Yildirir, Aylin; Kuscu, Esra; Muderrisoglu, Haldun; 25430415
Objective: In healthy women, there is a progressive age-related increase in myocardial mass that is not seen in their male counterparts and occurs primarily in postmenopausal women. Raloxifene is a selective estrogen receptor modulator that has estrogenic actions on bone and the cardiovascular system. The aim of this study was to investigate the effect of raloxifene on myocardial hypertrophy in postmenopausal patients. Methods: A total of 22 postmenopausal osteoporotic women were included in this open-label, randomized, prospective, controlled study. Patients were randomized into two groups: 11 of the patients (group 1) were treated with raloxifene 60 mg/day, and the other 11 patients (group 2) were defined as the control group. Quantitative 2-dimensional and M-mode echocardiographic examination was performed in all patients at the beginning and repeated at the end of the 6-month follow-up period. Left ventricle mass (LVM) and left ventricle mass index (LVMI) were calculated for all patients. Results: The mean age of the patients was 57.2 +/- 3.9 years, and baseline clinical characteristics and echocardiographic parameters were similar between the two groups. After 6 months of raloxifene treatment, there was no difference in echocardiographic parameters of LVM and LVMI compared with the control group (201.2 +/- 25.9 gr vs. 169.7 +/- 46.2 gr, p=0.14 and 120.4 +/- 25.9 gr/m(2) vs. 105.5 +/- 26.3 gr/m(2), p=0.195, respectively). There was also no significant difference in LVM and LVMI in the within-group analysis of both groups. Conclusion: Raloxifene therapy does not affect myocardial hypertrophy in postmenopausal women after 6 months of treatment.